Table 2.
Proportion and absolute number of all ART clients on MMD in 21 PEPFAR‐supported countries (October 2019–December 2020)
| Quarter | Clients on ART | 3–5MMD (%) | 6MMD (%) | Total MMD (%) |
|---|---|---|---|---|
| Q4 2019 | 10,372,711 | 4,180,036 (40%) | 913,525 (9%) | 5,093,561 (49%) |
| Q1 2020 | 10,703,679 | 5,198,528 (49%) | 1,014,704 (9%) | 6,213,232 (58%) |
| Q2 20201 | 11,121,591 | 6,134,728 (55%)a | 1,917,047 (17%)b | 8,051,775 (72%)c |
| Q3 2020 | 11,476,916 | 6,196,129 (54%) | 2,308,130 (20%) | 8,504,259 (74%) |
| Q4 2020 | 11,656,878 | 6,227,107 (53%) | 2,517,943 (22%) | 8,745,050 (75%) |
1Two‐proportion Z‐test comparing MMD % for Q2 2020 (COVID‐19) versus Q4 2019 (pre‐COVID‐19): (a) for 3–5 MMD, p<0.001; (b) for 6MMD, p < 0.001; and (c) for total MMD, p <0.001.
ART, antiretroviral therapy; MMD, multi‐month dispensing; PEPFAR, the United States President's Emergency Plan for AIDS Relief; 3‐5MMD, 3‐5‐month multi‐months dispensing; 6MMD, 6‐months multi‐month dispensing.